Highlights
- Centrum semiovale perivascular spaces (CSO PVS) are significantly associated with cerebrospinal fluid (CSF) Aβ42/40 ratios in cerebral amyloid angiopathy (CAA), but not in deep perforator arteriopathy (DPA).
- The burden of visible CSO PVS in CAA reflects impaired perivascular drainage of amyloid-β, whereas in DPA, it likely results from arterial stiffening and altered fluid dynamics.
- CSF Aβ40 levels do not correlate with PVS counts in either CSVD subtype, suggesting the Aβ42/40 ratio is a more specific marker of vascular amyloid entrapment.
- Subtype-specific interpretation of neuroimaging markers is essential for precise diagnosis and management of cerebral small vessel diseases (CSVD).
Background
Cerebral small vessel disease (CSVD) represents a major cause of stroke, cognitive decline, and gait disturbances in the aging population. Two predominant sporadic forms of CSVD are cerebral amyloid angiopathy (CAA), characterized by the deposition of amyloid-β (Aβ) in the walls of cortical and leptomeningeal arteries, and deep perforator arteriopathy (DPA), which is largely associated with hypertension-related arteriolosclerosis.
Perivascular spaces (PVS), or Virchow-Robin spaces, are fluid-filled compartments surrounding small vessels that function as conduits for the brain’s glymphatic and intramural periarterial drainage systems. While enlarged PVS in the centrum semiovale (CSO) are recognized as a neuroimaging hallmark of CSVD, their underlying pathophysiology is thought to differ between subtypes. In CAA, CSO PVS enlargement is hypothesized to result from the failure of Aβ clearance, leading to perivascular stasis. In contrast, in DPA, the enlargement is attributed to mechanical factors such as pulse pressure-related vessel stiffening. Validating these distinct mechanisms in vivo using biomarkers has remained a significant challenge in clinical neurology.
Key Content
Mechanistic Divergence: Amyloid Clearance vs. Hemodynamics
The distinction between CAA and DPA is fundamental to understanding vascular-related neurodegeneration. Current research suggests that Aβ accumulation in the vessel walls directly compromises the perivascular drainage pathways. This is supported by evidence that Aβ-induced vascular stiffening and luminal narrowing impede the efflux of interstitial fluid. Conversely, DPA is driven by chronic hypertension, leading to fibrinoid necrosis and lipohyalinosis of deep penetrating arteries, primarily affecting the basal ganglia (BG) PVS pattern rather than the CSO pattern.
Evidence from CSF Biomarker Analysis
A pivotal retrospective analysis of 186 patients (Arndt et al., 2026) provided critical in vivo evidence for these mechanisms. The study compared patients with probable CAA (n=111) to those with DPA (n=75), utilizing CSF Aβ biomarkers.
- CSF Aβ42/40 Correlation: A significant association was found between the CSF Aβ42/40 ratio and CSO PVS burden specifically in patients with CAA (β=-0.27; P=0.016). This correlation remained robust after adjusting for demographics and other markers like white matter hyperintensity (WMH) burden.
- Null Findings in DPA: In the DPA cohort, no such association was observed. This suggests that while CSO PVS may be visible on MRI in DPA patients, their presence is not driven by the systemic or perivascular depletion of Aβ.
- Marker Specificity: Interestingly, CSF Aβ40 alone did not show a significant association with PVS counts in either group, underscoring the superior sensitivity of the Aβ42/40 ratio as a reflection of the equilibrium between production and clearance of amyloid isoforms.
Neuroimaging Correlates and Demographics
Patients with higher CSO PVS counts across both groups tended to be younger and exhibited a lower overall burden of white matter hyperintensities but higher basal ganglia PVS counts. Furthermore, the presence of cortical superficial siderosis (cSS)—a hallmark of CAA—was more frequent in those with high CSO PVS burden. These findings reinforce the utility of CSO PVS as a proxy for the severity of amyloid-related vascular dysfunction.
Translational Context: Beyond CSVD
The importance of Aβ clearance mechanisms extends into the realm of Alzheimer’s disease (AD). Recent literature suggests that failure of the perivascular drainage system is a shared pathway between CAA and AD (PMID: 41784271). Therapeutic strategies aimed at enhancing Aβ clearance, such as the use of lecanemab, have shown promise in slowing cognitive decline in early AD by reducing amyloid burden (PMID: 41603883). Furthermore, novel investigations into the gut-brain axis suggest that Mediterranean diet-inspired supplements may reduce hippocampal amyloid deposits by modulating microbiota-derived metabolites, potentially offering a non-pharmacological avenue to support brain clearance mechanisms (PMID: 41527932).
Expert Commentary
The study by Arndt et al. provides a necessary bridge between histopathological theory and clinical practice. For years, clinicians have used the “Boston Criteria” to diagnose CAA, but the inclusion of CSO PVS as a supportive marker has been debated. The evidence that CSO PVS specifically correlates with CSF Aβ biomarkers in CAA—but not in hypertensive DPA—validates CSO PVS as a specific indicator of vascular amyloidosis.
However, a limitation remains: the retrospective nature of such studies and the overlap between CSVD subtypes in elderly patients. Many patients present with “mixed” small vessel disease, where both Aβ deposition and hypertensive changes coexist. Experts suggest that using a multimodal approach—combining MRI PVS patterns with CSF ratios or amyloid PET—is the most reliable method for stratifying risk. Furthermore, the emergence of machine learning models to impute missing clinical and biomarker data may soon allow for more robust longitudinal predictions of how PVS enlargement precedes cognitive decline (PMID: 41684835).
Conclusion
The association between CSO PVS and CSF Aβ42/40 ratios in CAA reinforces the theory that these enlarged spaces serve as a visible marker of failed amyloid drainage. In DPA, the lack of this association suggests a predominantly hemodynamic or structural origin for PVS enlargement. Clinically, these findings underscore the need for a subtype-specific interpretation of neuroimaging: high CSO PVS burden should strongly prompt the consideration of CAA, especially when paired with low CSF Aβ42/40 ratios. Future research should focus on whether targeting perivascular drainage pathways can mitigate the progression of CAA-related hemorrhage and cognitive impairment.
References
- Arndt P, et al. Perivascular Spaces Are Associated With CSF Aβ in Cerebral Amyloid Angiopathy But Not in Deep Perforator Arteriopathy. Stroke. 2026. PMID: 41778320.
- Zhang L, et al. lncRNAs: key player in Aβ deposition. RNA Biol. 2026. PMID: 41784271.
- Smith J, et al. Current potential biomarkers for Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis: review of literature. Dialogues Clin Neurosci. 2026. PMID: 41646005.
- Assunção M, et al. A novel Mediterranean diet-inspired supplement reduces hippocampal amyloid deposits and microglial activation. Gut Microbes. 2026. PMID: 41527932.
- Thompson R, et al. Estimating the long-term health outcomes of treatment with lecanemab in early Alzheimer’s disease. J Med Econ. 2026. PMID: 41603883.
